Thomas & Betts Corporation (NYSE:TNB): Baird believes the chances for the emergence of an alternative suitor with a superior offer for Thomas and Betts (NYSE:TNB) is remote. The firm cited the strategic merits of the deal with ABB (NYSE:ABB) and the premium price paid. Shares are Outperform rated and the price target is raised to $75 from $57. The shares closed at $71.31, up $13.36, or 23.05%. They have traded in a 52-week range of $37.51 to $61.88.
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): Baird raised its price target on Amylin following its FDA approval of Byduereon. The firm said the drug’s approval removes the company’s downside risk and makes a successful US partnership possible. Shares are Outperform rated. The shares closed at $14.26, up $2.12, or 17.46%. They have traded in a 52-week range of $8.03 to $16.58.
InvenSense Inc (NYSE:INVN): On Friday, after InvenSense reported higher than expected EPS for its December quarter, Oppenheimer expects the company to benefit from the launch of Microsoft’s (NASDAQ:MSFT) Windows 8 and smart TVs. The firm maintains an Outperform rating. The shares closed at $16.29, up $1.77, or 12.19%. They have traded in a 52-week range of $8.25 to $16.74.
Ubiquiti Networks Inc (NASDAQ:UBNT): Ubiquiti Networks initiated with a buy at Wunderlich with a target $25. The shares closed at $24.42, up $1.86, or 8.24%. They have traded in a 52-week range of $16.25 to $23.04.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.